Prevention That Pays: Vitamin D and Better Benefit Design

Optimizing vitamin D 25-OH blood levels continues to warrant support as part of a proactive medical and pharmacy benefits strategy. When low serum levels are identified, vitamin D3 supplementation is a low-cost, evidence-aligned intervention with meaningful potential impact. Annual immunotherapy costs for multiple sclerosis can approach $80,000, while vitamin D3 supplementation averages roughly $52 per year. That contrast alone highlights the value of prevention. Emerging evidence shows that higher vitamin D intake from food and supplements is associated with a significantly lower risk of developing multiple sclerosis among women, supporting the role of vitamin D itself in modifying disease risk (Kapali et al., 2025). Smart benefit design should therefore invest in trusted communication channels that allow timely education and engagement around interventions like this. Preventing even one case of MS improves quality of life for the individual and delivers substantial financial benefit to the broader risk pool.

Kapali, A., Daltveit, A. K., Myhr, K., et al. (2025). Vitamin D intake and multiple sclerosis risk in the Norwegian Mother, Father and Child cohort. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2025-337300